Persistência do canal arterial

Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J. 2021 Feb 11;42(6):563-645.Texto completo

Hamrick SEG, Sallmon H, Rose AT, et al. Patent ductus arteriosus of the preterm infant. Pediatrics. 2020 Nov;146(5):e20201209.Texto completo  Resumo

Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78.Texto completo  Resumo

John AS, Jackson JL, Moons P, et al. Advances in managing transition to adulthood for adolescents with congenital heart disease: a practical approach to transition program design: a scientific statement from the American Heart Association. J Am Heart Assoc. 2022 Apr 5;11(7):e025278.Texto completo  Resumo

1. Kitterman JA, Edmunds LH Jr, Gregory GA, et al. Patent ductus arteriosus in premature infants, incidence, relation to pulmonary disease and management. N Engl J Med. 1972;287:473-477. Resumo

2. Moore P, Brook MM, Heymann MA. Patent ductus arteriosus. In: Moss and Adams heart disease in infants, children and adolescents. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001.

3. Gittenburger-De Groot AC, van Ertbruggen I, Moulaert AJ, et al. The ductus arteriosus in the preterm infant: histologic and clinical observations. J Pediatr. 1980;96:88-93. Resumo

4. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107:E32.Texto completo  Resumo

5. Lloyd TR, Beekman RH III. Clinical silent patent ductus arteriosus. Am Heart J. 1994;127:1664-1665.

6. Rothman KJ, Fyler DC. Sex, birth order, and maternal age characteristics of infants with congenital heart defects. Am J Epidemiol. 1976;104:527-534. Resumo

7. Miao CY, Zuberbuhler JS, Zuberbuhler JR. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol. 1988;12:224-228. Resumo

8. Sood E, Newburger JW, Anixt JS, et al. Neurodevelopmental outcomes for individuals with congenital heart disease: updates in neuroprotection, risk-stratification, evaluation, and management: a scientific statement from the American Heart Association. Circulation. 2024 Mar 26;149(13):e997-1022.Texto completo  Resumo

9. Moon-Grady AJ, Donofrio MT, Gelehrter S, et al. Guidelines and recommendations for performance of the fetal echocardiogram: an update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2023 Jul;36(7):679-723.Texto completo

10. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998;50:35-58.Texto completo  Resumo

11. Thebaud B, Michelakis ED, Wu XC, et al. Oxygen-sensitive Kv channel gene transfer confers oxygen responsiveness to preterm rabbit and remodeled human ductus arteriosus: implications for infants with patent ductus arteriosus. Circulation. 2004;110:1372-1379.Texto completo  Resumo

12. Michelakis E, Rebeyka I, Bateson J, et al. Voltage-gated potassium channels in human ductus arteriosus. Lancet. 2000;356:134-137. Resumo

13. Olley PM, Coceani F. Lipid mediators in the control of the ductus arteriosus. Am Rev Respir Dis. 1987;136:218-219. Resumo

14. Gittenberger-de Groot AC, Strengers JL, Mentink M, et al. Histologic studies on normal and persistent ductus arteriosus in the dog. J Am Coll Cardiol. 1985;6:394-404. Resumo

15. Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the role of postnatal constriction, hypoxia and gestation. Pediatr Res. 1999;45:19-29.

16. Clyman RI, Mauray F, Roman C, et al. Effect of gestational age on ductus arteriosus response to circulating prostaglandin E2. J Pediatr. 1983;102:907-911. Resumo

17. Rudolph AM, Mayer FE, Nadas AS, et al. Patent ductus arteriosus. A clinical and hemodynamic study of patients in the first year of life. Pediatrics. 1958;22:892-904. Resumo

18. Baylen BG, Ogata H, Oguchi K, et al. The contractility and performance of the pre-term left ventricle before and after early patent ductus arteriosus occlusion in surfactant-treated lambs. Pediatr Res. 1985;19:1053-1058. Resumo

19. Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr. 2000 Jul;137(1):68-72. Resumo

20. Marshall DD, Kotelchuck M, Young TE, et al. Risk factors for chronic lung disease in the surfactant era: A North Carolina population-based study of very low birth weight infants. Pediatrics. 1999 Dec;104(6):1345-50. Resumo

21. Rojas MA, Gonzalez A, Bancalari E, et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995 Apr;126(4):605-10. Resumo

22. Dudell GG, Gersony WM. Patent ductus arteriosus in neonates with severe respiratory disease. J Pediatr. 1984 Jun;104(6):915-20. Resumo

23. Osborn DA, Evans N, Kluckow M. Hemodynamic and antecedent risk factors of early and late periventricular/intraventricular hemorrhage in premature infants. Pediatrics. 2003 Jul;112(1 Pt 1):33-9. Resumo

24. Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):184-8. Resumo

25. Hoffman JI, Buckberg GD. Regional myocardial ischemia: causes, prediction, and prevention. Vasc Surg. 1974;18:115-130. Resumo

26. Rudolph AM, Drorbaugh JE, Auld PA, et al. Studies on the circulation in the neonatal period. The circulation in the respiratory distress syndrome. Pediatrics. 1961;27:551-566. Resumo

27. Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983 Jun;102(6):895-906. Resumo

28. Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117:1113-1121. Resumo

29. Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2010;(1):CD001079. Resumo

30. Gibson S, Lewis KC. Congenital heart disease following maternal rubella during pregnancy. Am J Dis Child. 1952;83:317-319. Resumo

31. Campbell M. Natural history of patent ductus arteriosus. Br Heart J. 1968 Jan;30(1):4-13. Resumo

32. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. 2006 Oct 24;114(17):1873-82.Texto completo  Resumo

33. Clyman RI, Mauray F, Roman C, et al. Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs. J Pediatr. 1980;97:455-461. Resumo

34. Nora JJ. Multifactorial inheritance hypothesis for the etiology of congenital heart diseases. The genetic-environmental interaction. Circulation. 1968;38:604-617. Resumo

35. Char F. Peculiar facies with short philtrum, duck-bill lips, ptosis and low-set ears a new syndrome? Birth Defects Orig Artic Ser. 1978;14:303-305. Resumo

36. Mani A, Meraji SM, Houshyar R, et al. Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. Proc Nat Acad Sci USA. 2002;99:15054-15059.Texto completo  Resumo

37. Bevilacqua E, Brunelli R, Anceschi MM. Review and meta-analysis: benefits and risks of multiple courses of antenatal corticosteroids. J Matern Fetal Neonatal Med. 2010;23:244-260. Resumo

38. Schneider DJ. The patent ductus arteriosus in term infants, children, and adults. Semin Perinatol. 2012 Apr;36(2):146-53. Resumo

39. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J. 2021 Feb 11;42(6):563-645.Texto completo

40. Gibson GA. Persistence of the arterial duct and its diagnosis. Edinburgh Med J. 1900;8:1-5.

41. Expert Panel on Cardiac Imaging:; Woodard PK, Ho VB, et al. ACR appropriateness criteria® known or suspected congenital heart disease in the adult. J Am Coll Radiol. 2017 May;14(5s):S166-76.Texto completo  Resumo

42. Wasserman MA, Shea E, Cassidy C, et al. Recommendations for the adult cardiac sonographer performing echocardiography to screen for critical congenital heart disease in the newborn: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2021 Mar;34(3):207-22.Texto completo  Resumo

43. Stevenson JG, Kawabori I, Guntheroth WG. Pulsed doppler echocardiographic diagnosis of patent ductus arteriosus: sensitivity, specificity, limitations, and technical features. Cathet Cardiovasc Diagn. 1980;6(3):255-63. Resumo

44. Gokulakrishnan G, Kulkarni M, He S, et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates. Cochrane Database Syst Rev. 2022 Dec 8;12(12):CD013129. Resumo

45. Urquhart DS, Nicholl RM. How good is clinical examination at detecting a significant patent ductus arteriosus in the preterm neonate? Arch Dis Child. 2003 Jan;88(1):85-6.

46. Zanardo V, Milanesi O, Trevisanuto D, et al. Early screening and treatment of "silent" patent ductus arteriosus in prematures with RDS. J Perinat Med. 1991;19:291-295. Resumo

47. Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol. 2001;6:63-73. Resumo

48. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2003 Nov;88(6):F464-6.Texto completo  Resumo

49. Hundscheid T, El-Khuffash A, McNamara PJ, et al. Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity. Eur J Pediatr. 2022 Jun;181(6):2459-68.Texto completo  Resumo

50. Hamrick SEG, Sallmon H, Rose AT, et al. Patent ductus arteriosus of the preterm infant. Pediatrics. 2020 Nov;146(5):e20201209.Texto completo  Resumo

51. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010;(7):CD000174. Resumo

52. Mitra S, Gardner CE, MacLellan A, et al. Prophylactic cyclo-oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta-analysis. Cochrane Database Syst Rev. 2022 Apr 1;(4):CD013846.Texto completo  Resumo

53. Mitra S, de Boode WP, Weisz DE, et al. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023 Apr 11;4(4):CD013588.Texto completo  Resumo

54. Little DC, Pratt TC, Blalock SE, et al. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg. 2003 Mar;38(3):492-6. Resumo

55. Ohlsson A, Bottu J, Govan J, et al. Effect of indomethacin on cerebral blood flow velocities in very low birth weight neonates with a patent ductus arteriosus. Dev Pharmacol Ther. 1993;20(1-2):100-6. Resumo

56. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020 Feb 11;2:CD003481.Texto completo  Resumo

57. Canadian Paediatric Society. Management of the patent ductus arteriosus in preterm infants. Feb 2022 [internet publication].Texto completo

58. Al-Turkait A, Szatkowski L, Choonara I, et al. Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study. BMJ Paediatr Open. 2022 Mar;6(1):e001424.Texto completo  Resumo

59. Backes CH, Hill KD, Shelton EL, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022 Sep 6;11(17):e025784.Texto completo  Resumo

60. Mitra S, Florez ID, Tamayo ME, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA. 2018 Mar 27;319(12):1221-1238.Texto completo  Resumo

61. Yeung T, Shahroor M, Jain A, et al. Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis. J Neonatal Perinatal Med. 2022;15(3):501-10. Resumo

62. Neumann R, Schulzke SM, Bührer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology. 2012;102(1):9-15. Resumo

63. Erdeve O, Yurttutan S, Altug N, et al. Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2012 Jul;97(4):F279-83. Resumo

64. Evans P, O'Reilly D, Flyer JN, et al. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2021 Jan 15;1:CD013133.Texto completo  Resumo

65. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2007;(1):CD003480.Texto completo  Resumo

66. Attridge JT, Kaufman DA, Lim DS, et al. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2009 May;94(3):F178-82. Resumo

67. Hundscheid T, Jansen EJS, Onland W, et al. Conservative management of patent ductus arteriosus in preterm infants - A systematic review and meta-analyses assessing differences in outcome measures between randomized controlled trials and cohort studies. Front Pediatr. 2021;9:626261.Texto completo  Resumo

68. Mitra S, Scrivens A, von Kursell AM, et al. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev. 2020 Dec 10;12:CD013278.Texto completo  Resumo

69. Hundscheid T, Onland W, Kooi EMW, et al. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023 Mar 16;388(11):980-90.Texto completo  Resumo

70. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, et al. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed. 2007 Jul;92(4):F244-7. Resumo

71. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2014;(12):CD000503.Texto completo  Resumo

72. Gross RE, Hubbard JP. Surgical ligation of a patent ductus arteriosus: a report of first successful case. JAMA. 1939;112:729-731. Resumo

73. Koehne PS, Bein G, Alexi-Meskhishvili V, et al. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med. 2001;29(4):327-34. Resumo

74. Demir T, Oztunc F, Cetin G, et al. Patency or recanalization of the arterial duct after surgical double ligation and transfixion. Cardiol Young. 2007 Feb;17(1):48-50. Resumo

75. Lee LC, Tillet A, Tulloh R. Outcome following patent ductus arteriosus ligation in premature infants: a retrospective cohort analysis. BMC Pediatr. 2006 May 11;6:15.Texto completo  Resumo

76. Malviya M, Ohlsson A, Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2013;(3):CD003951.Texto completo  Resumo

77. Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Ped. 2009 Jun;154(6):873-6. Resumo

78. Mosalli R, Alfaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev. 2008;(1):CD006181. Resumo

79. Yee WH, Scotland J; Evidence-based Practice for Improving Quality (EPIQ) Evidence Review Group. Does primary surgical closure of the patent ductus arteriosus in infants <1500 g or ≤32 weeks' gestation reduce the incidence of necrotizing enterocolitis? Paediatr Child Health. 2012 Mar;17(3):125-8.Texto completo  Resumo

80. Laborde F, Folliguet TA, Etienne PY, et al. Video-thoracoscopic surgical interruption of patent ductus arteriosus. Routine experience in 332 pediatric cases. Eur J Cardiothorac Surg. 1997 Jun;11(6):1052-5. Resumo

81. Grifka RG. Transcatheter closure of the patent ductus arteriosus. Catheter Cardiovasc Interv. 2004 Apr;61(4):554-70.

82. Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation. 2021 May 18;143(20):e963-78.Texto completo  Resumo

83. Butera G, De Rosa G, Chessa M, et al. Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart. 2004 Dec;90(12):1467-70.Texto completo  Resumo

84. Masura J, Walsh KP, Thanopoulous B, et al. Catheter closure of moderate- to large-sized patent ductus arteriosus using the new Amplatzer duct occluder: immediate and short-term results. J Am Coll Cardiol. 1998 Mar 15;31(4):878-82. Resumo

85. Masura J, Tittel P, Gavora P, et al. Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. Am Heart J. 2006 Mar;151(3):755.e7-755.e10. Resumo

86. Magee AG, Huggon IC, Seed PT, et al. Transcatheter coil occlusion of the arterial duct; results of the European Registry. Eur Heart J. 2001 Oct;22(19):1817-21.Texto completo  Resumo

87. Al-Ata J, Arfi AM, Hussain A, et al. The efficacy and safety of the Amplatzer ductal occluder in young children and infants. Cardiol Young. 2005 Jun;15(3):279-85. Resumo

88. Fischer G, Stieh J, Uebing A, et al. Transcatheter closure of persistent ductus arteriosus in infants using the Amplatzer duct occluder. Heart. 2001 Oct;86(4):444-7.Texto completo  Resumo

89. Fisher RG, Moodie DS, Sterba R, et al. Patent ductus arteriosus in adults--long-term follow-up: nonsurgical versus surgical treatment. J Am Coll Cardiol. 1986 Aug;8(2):280-4. Resumo

90. Marelli A, Beauchesne L, Colman J, et al. Canadian Cardiovascular Society 2022 guidelines for cardiovascular interventions in adults with congenital heart disease. Can J Cardiol. 2022 Jul;38(7):862-96.Texto completo  Resumo

91. Hong TE, Hellenbrand WE, Hijazi ZM, et al. Transcatheter closure of patent ductus arteriosus in adults using the Amplatzer duct occluder: initial results and follow-up. Indian Heart J. 2002 Jul-Aug;54(4):384-9. Resumo

92. Pas D, Missault L, Hollanders G, et al. Persistent ductus arteriosus in the adult: clinical features and experience with percutaneous closure. Acta Cardiol. 2002 Aug;57(4):275-8. Resumo

93. Yilmaz AT, Yorulmaz FM, Ozturk OY, et al. Ligation in adult persistent ductus arteriosus. J Cardiovasc Surg (Torino). 1991 Sep-Oct;32(5):575-80. Resumo

94. Katsaras DN, Katsaras GN, Chatziravdeli VI, et al. Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022 Jul;88(7):3078-100.Texto completo  Resumo

95. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2020 Jan 27;1:CD010061.Texto completo  Resumo

96. Sellmer A, Bjerre JV, Schmidt MR, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013 Nov;98(6):F505-10. Resumo

97. Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009 Jan;123(1):e138-44. Resumo

98. Brooks JM, Travadi JN, Patole SK, et al. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed. 2005;90:F235-9. Resumo

99. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate. 2005;88(3):192-201. Resumo

100. Gentle SJ, Travers CP, Clark M, et al. Patent ductus arteriosus and development of bronchopulmonary dysplasia-associated pulmonary hypertension. Am J Respir Crit Care Med. 2023 Apr 1;207(7):921-8. Resumo

101. Wu TW, Noori S. Recognition and management of neonatal hemodynamic compromise. Pediatr Neonatol. 2021 Feb;62 Suppl 1:S22-9.Texto completo  Resumo

102. Majed B, Bateman DA, Uy N, et al. Patent ductus arteriosus is associated with acute kidney injury in the preterm infant. Pediatr Nephrol. 2019 Jun;34(6):1129-39. Resumo

103. Sung SI, Lee MH, Ahn SY, et al. Effect of nonintervention vs oral ibuprofen in patent ductus arteriosus in preterm infants: a randomized clinical trial. JAMA Pediatr. 2020 Aug 1;174(8):755-63.Texto completo  Resumo

104. El-Khuffash A, Bussmann N, Breatnach CR, et al. A pilot randomized controlled trial of early targeted patent ductus arteriosus treatment using a risk based severity score (The PDA RCT). J Pediatr. 2021 Feb;229:127-33. Resumo

105. Clyman RI, Liebowitz M, Kaempf J, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019 Feb;205:41-8.e6. Resumo

106. Mirea L, Sankaran K, Seshia M, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr. 2012 Oct;161(4):689-94.e1. Resumo

107. Madan JC, Kendrick D, Hagadorn JI, et al. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics. 2009 Feb;123(2):674-81. Resumo

108. Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007 Mar;150(3):229-34, 234.e1. Resumo

109. Chorne N, Leonard C, Piecuch R, et al. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007 Jun;119(6):1165-74. Resumo

110. Thilen U, Astrom-Olsson K. Does the risk of infective endarteritis justify routine patent ductus arteriosus closure? Eur Heart J. 1997;18:503-506.Texto completo  Resumo

111. Balzer DT, Spray TL, McMullin D, et al. Endarteritis associated with a clinically silent patent ductus arteriosus. Am Heart J. 1993;125:1192-1193. Resumo

112. Parthenakis FI, Kanakaraki MK, Vardas PE. Images in cardiology: silent patent ductus arteriosus endarteritis. Heart. 2000;84:619.Texto completo  Resumo

113. Jone PN, Ivy DD, Hauck A, et al. Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association. Circ Heart Fail. 2023 Jul;16(7):e00080.Texto completo  Resumo

114. Yan C, Zhao S, Jiang S, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007 Apr;93(4):514-8. Resumo

115. Dyamenahalli U, Smallhorn JF, Geva T, et al. Isolated ductus arteriosus aneurysm in the fetus and infant: a multi-institutional experience. J Am Coll Cardiol. 2000 Jul;36(1):262-9. Resumo

116. Jan SL, Hwang B, Fu YC, et al. Isolated neonatal ductus arteriosus aneurysm. J Am Coll Cardiol. 2002 Jan 16;39(2):342-7. Resumo

117. Mitchell RS, Seifert FC, Miller DC, et al. Aneurysm of the diverticulum of the ductus arteriosus in the adult. Successful surgical treatment in five patients and review of the literature. J Thorac Cardiovasc Surg. 1983 Sep;86(3):400-8. Resumo

118. McFaul RC, Keane JF, Nowicki ER, et al. Aortic thrombosis in the neonate. J Thorac Cardiovasc Surg. 1981 Mar;81(3):334-7. Resumo

119. Kovacs AH, Brouillette J, Ibeziako P, et al. Psychological outcomes and interventions for individuals with congenital heart disease: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2022 Aug;15(8):e000110.Texto completo  Resumo

120. National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Sep 2015 [internet publication].Texto completo

121. Graham TP Jr, Beekman RH 3rd, Allen HD, et al. ACCF/AHA/AAP recommendations for training in pediatric cardiology. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence (ACC/AHA/AAP Writing Committee to Develop Training Recommendations for Pediatric Cardiology). Circulation. 2005;112:2555-2580. Resumo

122. John AS, Jackson JL, Moons P, et al. Advances in managing transition to adulthood for adolescents with congenital heart disease: a practical approach to transition program design: a scientific statement from the American Heart Association. J Am Heart Assoc. 2022 Apr 5;11(7):e025278.Texto completo  Resumo